vs
Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $77.6M, roughly 1.2× Bioceres Crop Solutions Corp.). Vericel Corp runs the higher net margin — 25.0% vs -9.6%, a 34.6% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -16.8%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -8.4%).
Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
BIOX vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $77.6M | $92.9M |
| Net Profit | $-7.4M | $23.2M |
| Gross Margin | 46.8% | 78.7% |
| Operating Margin | 9.3% | 24.1% |
| Net Margin | -9.6% | 25.0% |
| Revenue YoY | -16.8% | 23.3% |
| Net Profit YoY | -20.2% | 17.3% |
| EPS (diluted) | $-0.12 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $92.9M | ||
| Q3 25 | $77.6M | $67.5M | ||
| Q2 25 | — | $63.2M | ||
| Q1 25 | $60.6M | $52.6M | ||
| Q4 24 | $98.8M | $75.4M | ||
| Q3 24 | $93.3M | $57.9M | ||
| Q2 24 | — | $52.7M | ||
| Q1 24 | $84.0M | $51.3M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | $-7.4M | $5.1M | ||
| Q2 25 | — | $-553.0K | ||
| Q1 25 | $-1.6M | $-11.2M | ||
| Q4 24 | $605.2K | $19.8M | ||
| Q3 24 | $-6.2M | $-901.0K | ||
| Q2 24 | — | $-4.7M | ||
| Q1 24 | $9.8M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | 46.8% | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | 39.4% | 69.0% | ||
| Q4 24 | 42.0% | 77.6% | ||
| Q3 24 | 40.2% | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | 50.8% | 68.9% |
| Q4 25 | — | 24.1% | ||
| Q3 25 | 9.3% | 5.1% | ||
| Q2 25 | — | -3.2% | ||
| Q1 25 | 1.5% | -24.3% | ||
| Q4 24 | 14.5% | 24.5% | ||
| Q3 24 | 2.5% | -4.3% | ||
| Q2 24 | — | -11.5% | ||
| Q1 24 | 15.7% | -10.7% |
| Q4 25 | — | 25.0% | ||
| Q3 25 | -9.6% | 7.5% | ||
| Q2 25 | — | -0.9% | ||
| Q1 25 | -2.6% | -21.4% | ||
| Q4 24 | 0.6% | 26.3% | ||
| Q3 24 | -6.6% | -1.6% | ||
| Q2 24 | — | -8.9% | ||
| Q1 24 | 11.6% | -7.5% |
| Q4 25 | — | $0.46 | ||
| Q3 25 | $-0.12 | $0.10 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | $-0.02 | $-0.23 | ||
| Q4 24 | $0.00 | $0.40 | ||
| Q3 24 | $-0.10 | $-0.02 | ||
| Q2 24 | — | $-0.10 | ||
| Q1 24 | $0.14 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.5M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $288.3M | $354.6M |
| Total Assets | $734.9M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | $15.5M | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | $38.5M | $112.9M | ||
| Q4 24 | $29.2M | $116.2M | ||
| Q3 24 | $32.3M | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | $16.4M | $110.6M |
| Q4 25 | — | $354.6M | ||
| Q3 25 | $288.3M | $321.9M | ||
| Q2 25 | — | $306.8M | ||
| Q1 25 | $345.0M | $295.5M | ||
| Q4 24 | $346.3M | $292.0M | ||
| Q3 24 | $346.0M | $257.5M | ||
| Q2 24 | — | $243.0M | ||
| Q1 24 | $348.5M | $233.9M |
| Q4 25 | — | $488.0M | ||
| Q3 25 | $734.9M | $453.3M | ||
| Q2 25 | — | $435.6M | ||
| Q1 25 | $798.2M | $424.6M | ||
| Q4 24 | $835.2M | $432.7M | ||
| Q3 24 | $827.3M | $390.4M | ||
| Q2 24 | — | $376.8M | ||
| Q1 24 | $836.1M | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $15.0M | ||
| Q3 25 | $14.4M | $22.1M | ||
| Q2 25 | — | $8.2M | ||
| Q1 25 | $23.3M | $6.6M | ||
| Q4 24 | $-5.4M | $22.2M | ||
| Q3 24 | $5.2M | $10.2M | ||
| Q2 24 | — | $18.5M | ||
| Q1 24 | $-17.4M | $7.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% | ||
| Q1 24 | — | -13.3% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% | ||
| Q1 24 | — | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -8.85× | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIOX
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
